ADTRALZA

This brand name is authorized in Estonia, Croatia, Ireland, Japan, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug ADTRALZA contains one active pharmaceutical ingredient (API):

1 Tralokinumab UNII GK1LYB375A - TRALOKINUMAB

Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to the type 2 cytokine interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptors. Tralokinumab neutralises the biological activity of IL-13 by blocking its interaction with the IL-13Rα1/IL-4Rα receptor complex. IL-13 is a major driver of human type 2 inflammatory disease, such as atopic dermatitis and inhibiting the IL-13 pathway with tralokinumab in patients decreases many of the mediators of type 2 inflammation. Read about Tralokinumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ADTRALZA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D11AH07		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1852310, 1852321, 1852332
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 399359
Country: JP	医薬品医療機器総合機構	Identifier(s): 4490409G1022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092843, 1092844, 1092845
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100455323
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68078001, W68078002, W68078003